Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
The company, which offers a variety of services through its online platform, including treatments for hair loss, erectile ...
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs
Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
STAT15h
Pharmalittle: We’re reading about copycat weight loss drugs, ADHD prescriptions spiking, and more
The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...
Business Insider23d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...
Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...
Why Hims & Hers Stock Tumbled on Tuesday
Hims & Hers Health ( HIMS 7.49%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...
Hims & Hers Health’s (HIMS) App Downloads Surged in February, Says Top Analyst
Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...